Replies to post #211059 on Biotech Values

[caravon]

The worldwide sale of Viekira ($263 13.1%) vs. Zepatier ($378 18.8%) indicates a gigantic ABBV's HCV marketing failure.

It also indicates, that going forward, GILD's HCV sale leadership status becomes very marginal.